Application of fusarium oxysporum in preparation of 1-dehydrodioscin
Through the bioconversion technology of Fusarium oxysporum SYfxl23.3, 1-dehydrogenated dysfunction was extracted from turmeric, which solved the problems of complex chemical synthesis and environmental damage, and achieved an environmentally friendly and low-cost preparation process with good industrial application prospects.
Patent Information
- Application Number
- CN202411359652.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-27
- Publication Date
- 2024-11-29
AI Technical Summary
The current chemical synthesis process of 1-dehydrogenated diosac is complex, has high cost and severe environmental damage, and lacks environmentally friendly preparation methods.
1-dehydrogenated diosporum SYfxl23.3 was prepared by bioconversion of Fusarium oxysporum SYfxl23.3, and the compound was extracted from turmeric by solid fermentation, and purified by ultrasonic extraction and trichloromethane redissolving volatile solvent.
The 1-dehydrogen dioxin preparation process with simple operation, mild reaction conditions, high conversion efficiency, environmental protection and low cost is realized, and has good industrial application prospects.
Smart Images

Figure CN119040426A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of microbial fermentation, relates to the synthesis of compounds by microbial fermentation catalysis, and specifically relates to the application of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin. Background Art
[0002] Studies have reported that 1-dehydrodiosgenin has a wide range of anti-cancer effects and has good market application prospects as an anti-cancer drug. Currently, 1-dehydrodiosgenin on the market is mostly prepared by chemical synthesis methods. Its synthesis process is mainly divided into two reaction stages. The first reaction stage: converting the 3-hydroxyl group of luxgenin into a carbonyl group and migrating the double bond from the 5-6 position to the 4-5 position; the second reaction stage: eliminating the hydroxyl group connected to the carbon atom at the 1 position and forming a double bond at the 1-2 position. The chemical synthesis steps are complicated and the reaction conditions are strict, which greatly increases the cost of the drug. In addition, the synthesis process requires high temperature, high acid, and high salt conditions, and the synthesis process causes serious damage to the environment. It is necessary to explore a new environmentally friendly preparation method.
[0003] Fusarium oxysporum is a type of imperfect fungus under the phylum Ascomycota. It is a soil-borne pathogenic fungus with a wide host range and has been widely used in the agricultural field. There are also reports on the application of Fusarium oxysporum in the preparation of compounds by microbial transformation, but there are no literature reports on the use of Fusarium oxysporum biotransformation to prepare 1-dehydrodiosgenin. Summary of the invention
[0004] In order to solve the above problems, the present invention provides an application of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin, and provides a novel environmentally friendly 1-dehydrodiosgenin preparation scheme. Compared with the prior art, the advantages of the present invention are that Fusarium oxysporum is applied to the preparation of 1-dehydrodiosgenin by biotransformation for the first time, and a process for preparing 1-dehydrodiosgenin by biotransformation is established, which overcomes the disadvantages of complex and high cost of chemical synthesis steps, avoids the disadvantage of chemical synthesis causing great damage to the environment, and provides a 1-dehydrodiosgenin preparation process with a simple preparation process and environmental protection.
[0005] The invention relates to application of Fusarium oxysporum in preparing 1-dehydrodiosgenin.
[0006] The specific Fusarium oxysporum was isolated from the underground stems (rhizomes) of Dioscorea zingiberensis by the inventor's laboratory, and the deposit information is as follows:
[0007] Strain name: SYfxl23.3
[0008] Classification name: Fusarium oxysporum
[0009] Date of receipt by the depository: October 27, 2023;
[0010] Time of issuance of preservation certificate: December 27, 2023;
[0011] Depository: China General Microbiology Center (CGMCC);
[0012] Deposit number: CGMCC No.40905.
[0013] Address: Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing.
[0014] Specifically, the present invention inoculates Fusarium oxysporum SYfxl23.3 on turmeric and prepares 1-dehydrodiosgenin through solid-state fermentation.
[0015] Furthermore, the main raw material of solid-state fermentation is turmeric, and the auxiliary raw materials include sucrose and beef extract.
[0016] Furthermore, the turmeric is a powder material passing through a 100-mesh sieve.
[0017] Furthermore, the components of the primary and secondary seed culture media used in the solid-state fermentation process are the same.
[0018] Furthermore, the components of the seed culture medium per liter include: 7.0 g sucrose, 2.0 g beef extract, 8.0 g Dioscorea rhizome powder, 0.5 g K2HPO4, 0.2 g KCl, and the balance is water.
[0019] Furthermore, stirring and adding 50% water during the solid-state fermentation process.
[0020] Furthermore, 1-dehydrodiosgenin is separated and obtained after solid-state fermentation, and the separation method in the initial purification stage is ultrasonic extraction.
[0021] Furthermore, the mass volume ratio of the solid fermentation product to the solvent petroleum ether in the ultrasonic extraction was 1:5.
[0022] Furthermore, after ultrasonic extraction, the volatile solvent is redissolved in chloroform for purification, and the 1-dehydrodiosgenin product is obtained by crystallization.
[0023] The present invention also relates to an application of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin, wherein the Fusarium oxysporum is Fusarium oxysporum SYfxl23.3.
[0024] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages.
[0025] The present invention is the first to apply a biologically active Fusarium oxysporum SYfxl23.3 isolated and screened by the laboratory to the biotransformation preparation of 1-dehydrodiosgenin.
[0026] The present invention uses Fusarium oxysporum SYfxl23.3 to directly prepare 1-dehydrodiosgenin from turmeric materials by solid-state fermentation, and explores a novel environmentally friendly 1-dehydrodiosgenin preparation process. The process has the advantages of simple operation, mild reaction conditions, high conversion efficiency, environmental protection, and low cost, can be applied to large-scale bioconversion to prepare 1-dehydrodiosgenin, and has good industrial application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0028] Figure 1 This is a diagram of the solid-state fermentation process.
[0029] Figure 2 It is a crystalline product of 1-dehydrodiosgenin separated and purified from solid-state fermentation products.
[0030] Figure 3 This is the H NMR spectrum of 1-dehydrodiosgenin.
[0031] Figure 4 This is the carbon NMR spectrum of 1-dehydrodiosgenin.
[0032] Figure 5 This is the DEPT spectrum of 1-dehydrodiosgenin.
[0033] Figure 6 This is the high-resolution mass spectrum of 1-dehydrodiosgenin.
[0034] Figure 7 It is the molecular structure formula of 1-dehydrodiosgenin.
[0035] Figure 8 This is the absolute configuration diagram of 1-dehydrodiosgenin.
[0036] Fig. 9 These are the results of the cell antiproliferation test of 1-dehydrodiosgenin.
[0037] Fig.10 This is the result of the anti-tumor mechanism experiment of 1-dehydrodioscin.
[0038] Fig.11 It is the result of safety test. DETAILED DESCRIPTION
[0039] The technical scheme of the present invention is described below in conjunction with the examples, but the present invention is not limited to the following examples. The experimental methods and detection methods described in each example are conventional methods unless otherwise specified; the reagents and materials are available on the market unless otherwise specified, and the % in the following examples are all mass percentages unless otherwise specified.
[0040] Example 1
[0041] This embodiment provides an application of Fusarium oxysporum SYfxl23.3.
[0042] The Fusarium oxysporum SYfxl23.3 used in this embodiment is a strain of biologically active Fusarium oxysporum isolated and screened from the underground stems (rhizomes) of Dioscorea zingiberensis purchased from Yongchun Agricultural Technology Co., Ltd., Baihe County, Ankang City. After identification, the fungus belongs to the genus Fusarium and has been deposited in the General Microbiological Center (CGMCC) of the China Microbiological Culture Collection Administration on October 27, 2023, with a deposit number of CGMCC No. 40905. The Fusarium oxysporum can be used as a raw material microorganism for preparing 1-dehydrodiosgenin.
[0043] Example 2
[0044] This embodiment provides a primary and secondary seed solution production process of Fusarium oxysporumSYfxl23.3 for preparing 1-dehydrodiosgenin.
[0045] Fusarium oxysporum SYfxl23.3 was inoculated on PDA medium for activation.
[0046] Prepare Fusarium oxysporum SYfx123.3 seed culture medium. The first and second level seed culture medium of Fusarium oxysporum SYfx123.3 are the same, collectively referred to as seed culture medium. Prepare the seed culture medium in the following proportions: 7.0 g sucrose, 2.0 g beef extract, 8.0 g yam rhizome powder, 0.5 g K2HPO4, 0.2 g KCl, and the balance water per liter of culture medium.
[0047] After the seed culture medium is prepared, it is sterilized by wet heat sterilization at 121° C. in a pressure cooker for 30 minutes. After sterilization, it is cooled to room temperature to obtain the seed culture medium.
[0048] The activated Fusarium oxysporum SYfxl23.3 strain was inoculated into the seed culture medium, cultured in a shake flask, with a shaker speed of 140 rpm and a temperature of 32° C., and fermented for 36 hours to prepare a first-level seed solution.
[0049] The first-level seed liquid was inoculated into the seed culture medium according to 6% of the second-level seed liquid, and the culture medium was fermented in a shake flask at a shaking speed of 140 rpm and a temperature of 32° C. for 24 hours to obtain the second-level seed liquid.
[0050] The primary seed culture medium and the secondary seed culture medium used in the preparation process of the above method are the same, the culture process is simpler, and the seed culture medium components are more suitable for the solid-state biotransformation of Fusarium oxysporum SYfxl23.3 to obtain 1-dehydrodiosgenin.
[0051] Example 3
[0052] This embodiment provides a process for preparing 1-dehydrodiosgenin by Fusarium oxysporum SYfxl23.3.
[0053] Take an appropriate amount of turmeric, crush it and pass it through a 100-mesh sieve to obtain the sieved powder, which is turmeric powder.
[0054] Sucrose and beef extract (biological reagent, Beijing Aoboxing Biotechnology Co., Ltd.) were weighed according to 4% of the secondary seed liquid of Fusarium oxysporum SYfxl23.3, and the sucrose and beef extract were evenly stirred to prepare a solid fermentation medium.
[0055] According to 60% of the secondary seed liquid of Fusarium oxysporum SYfxl23.3, turmeric powder was added to the secondary seed liquid of Fusarium oxysporum SYfxl23.3, and then a solid culture medium was added to carry out solid fermentation.
[0056] The solid-state fermentation temperature is 32°C, and the fermentation lasts for 8 days. During the fermentation process, the mixture is fully stirred and 50% of water is added. Figure 1 After the fermentation is completed, a solid-state fermentation product is obtained.
[0057] The solid-state fermentation product is placed in an oven at 50° C. for drying, and the dried product is crushed.
[0058] Then, 4 g of the crushed powder was sampled by a uniform method, added to 20 mL of petroleum ether, and extracted by 99 Hz ultrasound for 40 min. Then, the mixture was placed in a shaker at 150 rpm overnight, and the extract was collected in a plate the next day. The above sampling and mixing petroleum ether extraction steps were repeated three times, and the obtained extract was collected in the same plate. After the collected solution evaporated, the crude 1-dehydrodiosgenin was obtained.
[0059] Add chloroform to the crude 1-dehydrodiosgenin, redissolve, and dilute to 10 mL in a volumetric flask. After the liquid component in the resulting solution is completely volatilized, 1-dehydrodiosgenin crystals are obtained. The crystals of 1-dehydrodiosgenin are as follows: Figure 2 shown.
[0060] Compared with the prior art, this embodiment uses solid-state fermentation to prepare 1-dehydrodiosgenin from turmeric, the preparation steps are simple, the preparation process is clean and environmentally friendly, the obtained 1-dehydrodiosgenin has low cost, and has good industrial application prospects.
[0061] Example 4
[0062] This example is the structural identification of 1-dehydrodiosgenone prepared in Example 3.
[0063] By performing nuclear magnetic resonance analysis on the product obtained in Example 3, the molecular structure of the product can be analyzed and the chemical structure of the product can be determined.
[0064] like Figure 3 As shown: 1 In the H-NMR spectrum, the compound has three olefin protons in the low field region [(δH7.03, d, J=10.1Hz), (δH6.22, dd, J=10.1, 1.9Hz), (δH6.06, overlap)]. In the high field region, there are four methyl signals δH1.24 (3H, s), 0.96 (3H, d, J=6.9Hz), 0.84 (3H, s), 0.78 (3H, d, J=6.4Hz), and three hydrogen signals connected to oxygen 4.39 (1H, dd, 14.9, 7.6), 3.46 (1H, dd, 11.0, 2.9), 3.35 (t, 11.0). 1 In the H-NMR spectrum, there is serious overlap of hydrogen signals at δH1-2ppm, from which it can be preliminarily inferred that the compound may be a steroid.
[0065] like Figure 4 , Figure 5 As shown: 13The CNMR and DEPT135° spectra contain a total of 27 carbons, including 5 quaternary carbons (δC186.4, 169.2, 109.4, 43.7, 40.8), 10 secondary methyl groups (δC155.9, 127.6, 124.0, 80.6, 62.1, 55.3, 52.5, 41.7, 35.3, 30.4), 8 methylene groups (δC67.0, 39.6, 33.8, 32.9, 32.0, 31.4, 28.9, 22.8), and 4 methyl groups (δC18.9, 17.2, 16.6, 14.6). By comparing the characteristic signals of this type of compound, the chemical shift of C-3 is δC186.4ppm, C-22 is 109.4ppm, C-26 is assigned to 67.0ppm, and C-16 is assigned to 80.6ppm. 13 C spectrum and 1 The H spectrum data are shown in Table 1.
[0066] Table 11 - Dehydrodiosgenin 13 C spectrum and 1 H spectrum data
[0067]
[0068]
[0069] Figure 6 The LC-MS spectrum shows that the substance has a single peak, and Ms shows that the molecular weight of the substance is 411.2896 (M+1). The error between the theoretical value and the actual peak value is less than 5*10 -6 .
[0070] Figure 8 The crystal structure of the compound was simulated from the single crystal diffraction data. The single crystal of the compound molecule belongs to the monoclinic system, P212121 space group; the crystal structure was refined using OLEX2, R1 = 3.13%, wR2 = 7.51%, Flack parameter = 0.04 (19), and the characteristic symmetry elements in the crystal include three 21-helical axes; one unit cell contains 4 compound molecules. A single compound molecule contains 10 chiral carbon atoms, and the absolute configurations of the chiral carbons are C8 (S), C9 (S), C10 (R), C13 (S), C14 (S), C16 (S), C17 (R), C20 (S), C22 (R), C25 (R).
[0071] By comparing the NMR data, mass spectrum information, infrared data and single crystal absolute configuration data of the product of Example 3 in the Scifinder database, the results confirmed that the compound was 1-dehydrodiosgenin, and the molecular formula of the compound was C 27 H 38 O3, molecular structure Figure 7 .
[0072] The crystallographic data of 1-dehydrodiosgenone are deposited at the Cambridge Crystallographic Data Centre under the reference number CCDC-2325701.
[0073] In summary, the product of Example 3 was identified as: 1-dehydrodiosgenin, with a molecular formula of C 27 H 38 O3.
[0074] Example 5
[0075] This example is an anti-tumor test of 1-dehydrodiosgenin.
[0076] Cell lines and reagents: Hela, a549, and mad-mb-468 cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Trypsin, DMEM, penicillin, and streptomycin were from Gibco (Carlsbad, CA, USA).
[0077] Antitumor activity verification test: Hela, a549, and mad-mb-468 cell lines were cultured in high-glucose DMEM medium supplemented with 10% fetal bovine serum, 100U / ml penicillin, and 100U / ml streptomycin. All cell lines were incubated at 37°C and 5% CO2 in a humidified environment. A 30mM stock solution of the compound was prepared with chromatographic grade methanol and diluted to different final concentrations in the culture medium. The cells were counted after trypsin digestion, and about 3×10 cells / ml were added. 4 100ul cell suspension was added to each well of a 96-well plate, with about 3000 cells in each well. Three replicates were made for the same sample. 1-10μl of different concentrations of the drug to be tested was added to the culture plate for stimulation, and the plate was placed in an incubator at 37°C for culture. When changing the medium, a culture medium containing 10% CCK8 was added, and the cells were continued to be incubated at 37°C. The treatment with the addition of cell culture medium and CCK-8 solution without cells was used as a blank control. The OD values of different time periods were measured at 650nm using a Bio-Tek microplate reader ELX800, and the data processing results are shown in Table 2.
[0078] Table 2 The half inhibitory concentration (IC 50) values of 1-dehydrodiosgenin on Hala, A549 and Mad-mb468 cells at different action times
[0079]
[0080] The results of the anti-tumor activity test of 1-dehydrodioscinone showed that ( Fig. 9): After Hala, A549, and Mad-mb468 cells were exposed to 1-dehydrodiosgenin DMSO solutions of different concentrations and different action times, the cell viability decreased in a dose- and time-dependent manner within the test range (e.g. Fig. 9 The results are shown in Table 2, indicating that 1-dehydrodiosgenin has excellent anti-tumor activity. The half inhibitory concentration (IC50 value) of 1-dehydrodiosgenin on Hala, A549, and Mad-mb468 cells at different action times was calculated, and the data are shown in Table 2. It is worth noting that 1-dehydrodiosgenin showed significant efficacy on Hala, A549, and Mad-mb468 cells (IC50 = 6.59 μM, 5.43 μM, and 4.81 μM).
[0081] Studies have shown that steroid compounds with double bonds at carbon positions 1 and 3 show significant effects in inhibiting cell proliferation and other biological activities. Taking all factors into consideration, 1-dehydrodiosgenin is worth considering for further research on the design of drug precursors.
[0082] Example 6
[0083] This example is a study on the anti-tumor mechanism of 1-dehydrodiosgenin.
[0084] Hala, A549, and Mad-mb468 cells were treated with 1-Dehydrodiosgenone. After 48 hours, they were lysed in RIPA buffer on ice for 30 minutes and then centrifuged at 12,000 rpm for 10 minutes at 4°C. The supernatant was obtained and the protein concentration was determined using the BCA quantitative method. Equal amounts of protein were separated on a 10% SDS-PAGE gel and transferred to a polyvinylidene fluoride membrane. The membrane was pretreated and blocked, followed by primary and secondary antibody incubation. Finally, chemiluminescent substrates were used for luminescence, and the results were observed and recorded. Mini-PROTEAN Tetra WB System was used for subsequent analysis. The intensity of the protein bands was quantified using ImageJ analysis software, and the relative optical density value represented the protein concentration.
[0085] The experimental results are as follows Fig.10 As shown, treatment of Hala, A549, Mad-mb468 cells with 1-dehydrodiosgenin for 48 hours significantly increased the protein expression levels of caspase-3 (cleaved), PARP (cleaved), Bax, and Bad, and decreased the protein expression levels of caspase-3 and PARP. Quantitative analysis was performed by ImageJ software and presented in bar graphs, as shown in Fig.10As shown, the results showed that the optical density of apoptosis-related factors and apoptosis effector factors before and after 1-dehydrodioscin was treated with three types of tumor cells was significantly different. The above results show that 1-dehydrodioscin inhibits tumor cell proliferation mainly through the following three signaling pathways.
[0086] Intrinsic (mitochondrial) apoptosis pathway: Bax and Bad are pro-apoptotic members of the Bcl-2 family. They promote apoptosis by disrupting the mitochondrial membrane, leading to the release of cytochrome c. Bax is activated and translocated to the mitochondria in response to apoptotic signals, forming pores in the mitochondrial membrane. Bad binds to anti-apoptotic proteins such as Bcl-2 and Bcl-xL, inhibiting their function and thus promoting apoptosis.
[0087] Caspase activation pathway: Caspase-3 is one of the key enzymes for apoptosis. It exists in an inactive precursor form and is cleaved into an active form after being stimulated by apoptotic signals. Activated Caspase-3 can cleave a variety of intracellular substrates, leading to cell apoptosis.
[0088] PARP (poly ADP-ribose polymerase) pathway: PARP plays an important role in DNA damage repair. When cells are damaged by DNA, PARP is activated and participates in the DNA repair process. During apoptosis, activated Caspase-3 cuts PARP, causing it to lose its repair function and promote cell apoptosis.
[0089] This example confirms the tumor-suppressing effect of 1-dehydrodiosgenin at the protein level, and further explores the mechanism of action of 1-dehydrodiosgenin, suggesting that 1-dehydrodiosgenin induces apoptosis of Hala, A549, and Mad-mb468 cells through apoptosis-related pathways.
[0090] Example 7
[0091] This example is a safety test of 1-dehydrodiosgenin
[0092] All experimental procedures involving animals in this embodiment meet ethical requirements. The mouse model is C57, and the mice come from Lai'an Technology Co., Ltd. All mice are divided into two groups, each with ten mice. In the first group, each mouse is intraperitoneally injected with 100ul of 1-dehydrodiosgenin DMSO solution at a concentration of 10ug / mL every 2d, and each mouse in the second group is injected with the same volume of DMSO every 2d for control. Mice were killed after 14 days, and two groups of mice were dissected respectively to remove the heart, liver, brain, kidney, spleen, intestine and stomach. The removed organs were washed with physiological saline to remove excess blood and impurities. The weight of each organ was weighed separately with a precision balance, and the data was recorded. The weighing of each organ was repeated three times to ensure the accuracy of the data. The effect of 1-dehydrodiosgenin on the weight of the main organs of mice was evaluated, and each tissue was collected for HE staining observation. After fixing the tissue, it was trimmed into 25px*25px*5px, and dissolved in xylene for transparency after alcohol dehydration. The wax block was fixed on the slicer, the slice thickness was 5-8μm, and then it was attached to the glass slide after ironing and dried at 45℃. It was baked at 60℃ for 30min, washed with xylene, gradient ethanol, and distilled water. Harris hematoxylin staining was 3-8min, hydrochloric acid alcohol differentiation was performed for a few seconds, ammonia water turned blue, and eosin staining was performed for 1-3min. Finally, the slices were dehydrated and sealed, and examined under a microscope. The images were collected and analyzed by the Mingmei Microscopic Digital Imaging System.
[0093] The organ weights of mice in the control group and experimental group were compared by Graphpad Pism9.5 analysis ( Fig.11 ), the results showed that 1-dehydrodiosgenin had no significant effect on the organ weight of mice.
[0094] Tissues and organs of mice in the control group and experimental group were collected for sectioning and HE staining for pathological observation. Fig.11 The tissue sections of the heart, liver, brain, kidney, spleen, intestine and stomach were shown. Compared with the control group, the myocardial fibers of the experimental group were neatly arranged, the structure was intact, and there was no obvious pathological change; the hepatocytes were arranged normally, the liver sinusoid structure was clear, and there was no inflammation or necrosis; the brain tissue structure was clear, the nerve cells were arranged normally, and there was no inflammation or degeneration; the renal tubules and glomeruli were normal in structure, and there was no obvious pathological change; the spleen tissue structure was clear, the white pulp and red pulp were clearly divided, and there was no inflammation or necrosis; the intestinal mucosa structure was intact, the villi were neatly arranged, and there was no inflammation or ulcer; the gastric mucosa structure was intact, the glands were neatly arranged, and there was no inflammation or ulcer.
[0095] The results of tissue section pathology tests showed that there was no obvious pathological change in the organ tissue structure of mice injected with 1-dehydrodiosgenin in the abdomen compared with the control group; 1-dehydrodiosgenin did not cause inflammation or abnormal proliferation of normal cells; 1-dehydrodiosgenin had no obvious toxicity and side effects and had acceptable safety.
[0096] The embodiments described above are part of the embodiments of the present invention, but not all of them. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention claimed for protection, but only represents selected embodiments of the present invention. All other embodiments obtained without creative work and related deductions and substitutions made by ordinary technicians in the field under the conditions of the concept of the present invention belong to the scope of protection of the present invention.
Claims
1. An application of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin, characterized in that: 1-Dehydrodiosgenin was prepared by fermentation with Fusarium oxysporum SYfxl23.
3.
2. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 1, characterized in that: Fusarium oxysporum SYfxl23.3 was inoculated on turmeric to prepare 1-dehydrodiosgenin.
3. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 1, characterized in that: Preparation of 1-dehydrodiosgenin by solid-state fermentation.
4. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 3, characterized in that: The main raw material for solid-state fermentation is turmeric, and the auxiliary raw materials include sucrose and beef paste.
5. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 3 or 4, characterized in that: The components of the first and second level seed culture medium used in the fermentation process are the same. Each liter of the first and second level seed culture medium components contain: 7.0g sucrose, 2.0g beef extract, 8.0g Dioscorea rhizome powder, 0.5g K2HPO4, 0.2g KCl, and the balance is water.
6. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 2, characterized in that: The turmeric is turmeric powder passed through a 100-mesh sieve.
7. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 3, characterized in that: Stir and add 50% water during solid-state fermentation.
8. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 3, characterized in that: 1-Dehydrodiosgenin is separated and obtained after solid-state fermentation, and the separation method in the initial purification stage is ultrasonic extraction.
9. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 8, characterized in that: The mass volume ratio of solid fermentation product to solvent petroleum ether in ultrasonic extraction was 1:
5.
10. The use of Fusarium oxysporum in the preparation of 1-dehydrodiosgenin according to claim 3, characterized in that: The separation method after solid-state fermentation is chloroform purification.
